1FAK

HUMAN TISSUE FACTOR COMPLEXED WITH COAGULATION FACTOR VIIA INHIBITED WITH A BPTI-MUTANT

Summary for 1FAK

• Entry DOI: 10.2210/pdb1fak/pdb
• Descriptor: PROTEIN (BLOOD COAGULATION FACTOR VIIA), PROTEIN (SOLUBLE TISSUE FACTOR), PROTEIN (5L15), ... (8 entities in total)
• Functional Keywords: complex(serine protease-cofactor-ligand), blood coagulation, serine protease, complex, co-factor, receptor enzyme, inhibitor, gla, egf, complex (serine protease-cofactor-ligand), blood clotting
• Biological source: Homo sapiens (human); More
• Total number of polymer chains: 4
• Total formula weight: 75731.02

Authors

Zhang, E.,St Charles, R.,Tulinsky, A. (deposition date: 1998-12-28, release date: 1999-12-03, Last modification date: 2023-05-31)

Primary citation

Zhang, E.,St Charles, R.,Tulinsky, A.
Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant.
J.Mol.Biol., 285:2089-2104, 1999

PubMed Abstract: The event that initiates the extrinsic pathway of blood coagulation is the association of coagulation factor VIIa (VIIa) with its cell-bound receptor, tissue factor (TF), exposed to blood circulation following tissue injury and/or vascular damage. The natural inhibitor of the TF.VIIa complex is the first Kunitz domain of tissue factor pathway inhibitor (TFPI-K1). The structure of TF. VIIa reversibly inhibited with a potent (Ki=0.4 nM) bovine pancreatic trypsin inhibitor (BPTI) mutant (5L15), a homolog of TFPI-K1, has been determined at 2.1 A resolution. When bound to TF, the four domain VIIa molecule assumes an extended conformation with its light chain wrapping around the framework of the two domain TF cofactor. The 5L15 inhibitor associates with the active site of VIIa similar to trypsin-bound BPTI, but makes several unique interactions near the perimeter of the site that are not observed in the latter. Most of the interactions are polar and involve mutated positions of 5L15. Of the eight rationally engineered mutations distinguishing 5L15 from BPTI, seven are involved in productive interactions stabilizing the enzyme-inhibitor association with four contributing contacts unique to the VIIa.5L15 complex. Two additional unique interactions are due to distinguishing residues in the VIIa sequence: a salt bridge between Arg20 of 5L15 and Asp60 of an insertion loop of VIIa, and a hydrogen bond between Tyr34O of the inhibitor and Lys192NZ of the enzyme. These interactions were used further to model binding of TFPI-K1 to VIIa and TFPI-K2 to factor Xa, the principal activation product of TF.VIIa. The structure of the ternary protein complex identifies the determinants important for binding within and near the active site of VIIa, and provides cogent information for addressing the manner in which substrates of VIIa are bound and hydrolyzed in blood coagulation. It should also provide guidance in structure-aided drug design for the discovery of potent and selective small molecule VIIa inhibitors.

PubMed: 9925787
DOI: 10.1006/jmbi.1998.2452

Experimental method

X-RAY DIFFRACTION (2.1 Å)